KDM6B and depressive symptom measurement: Treatment with the demethylase Jmjd3 inhibitor GSK-J4 attenuated these changes, suggesting that Jmjd3 is involved in MS-induced depression susceptibility by enhancing neuroinflammation in the rat prefrontal cortex and hippocampus [67].